| Name | Title | Contact Details |
|---|
MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.
Vail Health provides 24/7 hospital, urgent-emergent care, orthopaedics, cardiology, physical therapy, endocrinology, internal medicine, cancer care, childbirth, surgery and plastics.
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.
Transforming the economics, usability, and accessibility of Endoscopic Ultrasound (EUS) for the benefit of patients, physicians, and payers.